BIO from the BAYOU · 2026-06-10 · 28 min
How can artificial intelligence help get the right drugs to the right patients faster, but without losing sight of the human side of healthcare? In this episode, host Elaine Hamm, PhD, sits down with Rafael Rosengarten, PhD, CEO and Co-Founder of Genialis, for a thoughtful conversation about the evolution of AI in biotech and its growing role in precision oncology. Drawing on more than a decade of experience at the intersection of machine learning and life sciences, Rafael shares how Genialis is building AI-powered foundation models of cancer biology to help pharmaceutical companies improve clinical trial success and accelerate drug development. The discussion also explores the promises and challenges of AI, from data quality and bias to the broader societal implications of increasingly intelligent technologies. In this episode, you'll discover: How AI foundation models are being used to reduce clinical trial failure in oncology. How new approaches to AI can unlock valuable insights from limited clinical datasets. The opportunities and risks of AI in healthcare, education, and society - and why human judgment remains essential.
Episode 143: Why Animal Health Is the Next Frontier for Biotech Innovation72 / 100Episode 142: How ARPA-H is Reimagining Women’s Health and Maternal CareEpisode 141: From Bench Science to Biotech Investment and Venture FundingEpisode 139: How to Understand Venture Math - The Numbers Behind Biotech Innovation (RE-RELEASE)Episode 138: Building Biotech Across Borders - Translational Science, Hearing Loss, and the Reality of Drug Development